Bruker unveils MyGenius PRO diagnostic system
The Bruker Microbiology & An infection Diagnostics division has introduced the European launch of its MyGenius PRO automated sample-to-answer (S2A) molecular diagnostics system on the European Society of Scientific Microbiology and Infectious Ailments (ESCMID) World 2026.
The platform is designed for the prognosis of infectious illnesses and options polymerase chain response expertise.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
It helps larger throughput operations, steady pattern loading and random entry options, automating your complete workflow from affected person pattern to diagnostic end result and supporting laboratories that require elevated effectivity and testing capability.
MyGenius PRO has already been put in in a European transplant middle, the place it’s used for routine testing for infectious illnesses.
At launch, the system’s in vitro diagnostic regulation (IVDR) menu will embrace exams for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from complete blood, in addition to BK virus (BKV) from urine. These exams are tailored to assist prognosis in immunocompromised sufferers.
Bruker has deliberate additional enlargement of the menu this 12 months to incorporate human immunodeficiency virus sort 1 (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), human herpes virus 6 (HHV-6) IVDR testing and extra pattern matrices.
The MyGenius PRO improvement was a collaboration between Bruker firm ELITechGroup and Hitachi Excessive-Tech, combining molecular evaluation, automation and technical experience.
In Japan, Hitachi Excessive-Tech will supply the platform as Labospect GA-5, which is able to use Bruker molecular diagnostic exams in accordance with Japanese diagnostic necessities.
This launch additional expands Bruker’s molecular diagnostics portfolio, together with InGenius, BeGenius and LiquidArray assays.
Bruker continues to deal with offering options to assist molecular, mobile and microscopic analyzes in varied analysis and diagnostic areas.
Earlier this 12 months, Bruker Power & Supercon Applied sciences (BEST) confirmed two multi-year provide agreements for MRI superconductors with world healthcare firms, totaling anticipated revenues of roughly $500 million.
